PMID:10928981

Citation	Schulte, R, Grassl, GA, Preger, S, Fessele, S, Jacobi, CA, Schaller, M, Nelson, PJ and Autenrieth, IB (2000) Yersinia enterocolitica invasin protein triggers IL-8 production in epithelial cells via activation of Rel p65-p65 homodimers. FASEB J. 14:1471-84
Abstract	Enteropathogenic Yersinia bacteria trigger the production of the proinflammatory chemokine IL-8, an important chemokine for the recruitment of polymorphonuclear leukocytes (PMN). Yersinia is resistant to phagocytosis by PMN, and the recruitment of these cells is thought to be part of a pathogenic strategy of Yersinia to establish infection by allowing the pathogen to gain access to, and disseminate within, host tissue. We report here that Yersinia expressing the outer membrane protein invasin triggers IL-8 production in epithelial cells. The 195 carboxyl-terminal amino acids of invasin when linked to latex beads are sufficient to trigger IL-8 production. By means of IL-8 promoter reporter gene assays and electrophoretic mobility shift assay experiments, the minimal optimal region of the IL-8 promoter responsive to invasin was identified and invasin-responsive control elements were characterized. Invasin-induced activation of the IL-8 promoter was found to be mediated through a previously identified NF-kappaB element. This NF-kappaB binding site preferentially binds Rel p65-p65 homodimers as well as some p50-p65 heterodimers in response to stimulation by invasin. Invasin-induced NF-kappaB activation correlated with degradation of IkappaBalpha and the inhibition of NF-kappaB by specific inhibitors of IkappaB activation blocked invasin-induced IL-8 secretion. Invasin-triggered IL-8 production does not depend on invasin-triggered uptake of bacteria, and is independent of a functional PI3-kinase. This report is the first to demonstrate the molecular basis of IL-8 production triggered by enteropathogenic bacteria. Together, these data elucidate the possible early pathomechanisms operating in Yersinia infection and may have implications for the design of novel therapeutics directed against this enteropathogen.
Links	PubMed
Keywords	Adhesins, Bacterial; Bacterial Proteins/genetics; Bacterial Proteins/metabolism; Binding, Competitive; Consensus Sequence/genetics; DNA/genetics; DNA/metabolism; DNA-Binding Proteins/metabolism; Dimerization; Endocytosis; Epithelial Cells/enzymology; Epithelial Cells/metabolism; Epithelial Cells/microbiology; Escherichia coli; HeLa Cells; Humans; I-kappa B Proteins; Interleukin-8/biosynthesis; Interleukin-8/genetics; Interleukin-8/metabolism; Microscopy, Electron; Microspheres; NF-kappa B/metabolism; NF-kappa B p50 Subunit; Phosphatidylinositol 3-Kinases/metabolism; Promoter Regions, Genetic/genetics; RNA, Messenger/genetics; RNA, Messenger/metabolism; Recombinant Proteins/genetics; Recombinant Proteins/metabolism; Sequence Deletion/genetics; Transcription Factor RelA; Transcriptional Activation; Yersinia enterocolitica/genetics; Yersinia enterocolitica/metabolism
edit table

Annotations

Gene product	Qualifier	GO Term	Evidence Code	with/from	Aspect	Extension	Notes	Status
HUMAN:IKBA	enables	GO:0008134: transcription factor binding	ECO:0000304: author statement supported by traceable reference used in manual assertion		F		Seeded From UniProt	complete

References

See Help:References for how to manage references in GONUTS.